OTC-BB:EMED

Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations

Retrieved on: 
Tuesday, March 14, 2023
PEMF, PNS, FSA, Portal, VNS, Pain, Low-level laser therapy, News, D, EMS, Wellness, CES, Defence Bioengineering and Electromedical Laboratory, Video game, Q2

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

Key Points: 
  • Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
  • During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
  • We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance.
  • And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

Sika Health and Electromedical Announce Partnership Enabling HSA/FSA Payments on Electromedical eCommerce Site

Retrieved on: 
Wednesday, January 25, 2023
HSA, Defence Bioengineering and Electromedical Laboratory, Health, Pain, FSA, Sika, Partnership, FDA, Patient, E-commerce, Chronic pain, Online shopping, Health insurance

SCOTTSDALE, Ariz., Jan. 25, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, and Sika Health, an HSA/FSA payment facilitator for eCommerce merchants, are pleased to announce a partnership enabling the direct acceptance of HSA/FSA payments on the Electromedical eCommerce website (electromedtech.com).

Key Points: 
  • SCOTTSDALE, Ariz., Jan. 25, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, and Sika Health, an HSA/FSA payment facilitator for eCommerce merchants, are pleased to announce a partnership enabling the direct acceptance of HSA/FSA payments on the Electromedical eCommerce website ( electromedtech.com ).
  • "This is a game-changer in terms of our ability to facilitate payments and tap into greater affordability without sacrificing margins," remarked Matthew Wolfson, CEO and Founder of Electromedical.
  • "Sika's payment technology is seamless and easy to use, and the Sika team has been exceptional to work with."
  • The partnership between Sika Health and Electromedical aims to close this gap and offer patients a seamless way to take full advantage of their benefits.

Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022

Retrieved on: 
Monday, December 5, 2022
Cloud, Stock dilution, Federal Food, Drug, and Cosmetic Act, Retirement, Negotiation, Pain, VNS, Sale, IDNA, Loss, Research, PNS, Q1, ALL, CES, Low-level laser therapy, FDA, Bioelectronics, Overalls, EMS, POD, Growth, University, Infinity, PEMF, Marketing, TENS, Renewable energy, Pharmaceutical industry, Medical imaging, Video game console, Risk management

SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.

Key Points: 
  • Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022
    SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.
  • Highlights for the three and nine months ended Sep 30, 2022
    Strong net sales during the quarter totaling approximately $280,000, beating both Q1 and Q2 2022 sales.
  • Net loss for the nine months ended Sep 30, 2022, of $2.64 million, a 60% improvement over net loss for the nine months ended Sep 30, 2021.
  • Approximately $900K in net financing used to expedite development of the new WellnessPro Infinity Flagship Device.

Electromedical Technologies Introduces the WellnessPro Infinity™

Retrieved on: 
Tuesday, November 1, 2022
Cloud, Goal, IDNA, CES, Retirement, CEO, PEMF, Defence Bioengineering and Electromedical Laboratory, Pain, Loss, Opioid epidemic, Research, Terminology, POD, Low-level laser therapy, University, NEW, Opioid, Private Securities Litigation Reform Act, VNS, Bioelectronics, EMS, Company, FDA, PNS, Portal, Federal Food, Drug, and Cosmetic Act, Forward-looking statement, IF, OTCQB, ALL, Risk management

SCOTTSDALE, Ariz., Oct. 31, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is very excited to introduce its new next-generation flagship device, the WellnessPro Infinity™.

Key Points: 
  • SCOTTSDALE, Ariz., Oct. 31, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. ( OTCQB: EMED ) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is very excited to introduce its new next-generation flagship device, the WellnessPro Infinity.
  • "The WellnessPro Infinity will set an entirely new standard in the Bioelectronics marketplace" remarked Electromedical Founder and CEO, Matthew Wolfson.
  • The NEW WellnessPro Infinity device features:
    One compact device that encompasses ALL electrotherapy modalities.
  • Our goal is to go to market with the WellnessPro Infinity first, then shortly after releasing the POD upon FDA 510k clearance."

Electromedical Update: Strong Q3 Sales Momentum, New Financing , Improved Supply Chain, Expanding Product Development and Production.

Retrieved on: 
Thursday, October 6, 2022
Loss, Research, Private Securities Litigation Reform Act, University, Q1, Goal, Company, CEO, Forward-looking statement, Terminology, FDA, Retirement, Poultry, Renewable energy, Mobile phone, Pharmaceutical industry, Risk management, Pain, Q3

Electromedical Founder and CEO, Matthew Wolfson, remarked, "Overall we saw around 24% stronger topline performance on a sequential quarterly basis in Q3, with additional orders in the pipeline for Q4.

Key Points: 
  • Electromedical Founder and CEO, Matthew Wolfson, remarked, "Overall we saw around 24% stronger topline performance on a sequential quarterly basis in Q3, with additional orders in the pipeline for Q4.
  • It was our strongest quarter of the year and the second strongest quarter of sales since the pandemic started."
  • Highlights for the three months ended Sep 30, 2022 (Q3)
    Strong overall sales totaling approximately $280K, beating both Q1 and Q2 2022 sales.
  • Closed approximately $900K in financing to expedite development of the new unit.

Electromedical's Flagship WellnessPro Plus Technology on Exhibit This Week at PAINWeek 2022 in Las Vegas from Sep 6-9

Retrieved on: 
Thursday, September 8, 2022
Chronic pain, Pharmacist, University, Booth, Therapy, CEO, Pain, Research, Private Securities Litigation Reform Act, Cosmopolitan Hotel, Heart, Loss, Physician, Pain management, Goal, Cosmopolitan Hotel and Restaurant, Retirement, Defence Bioengineering and Electromedical Laboratory, Company, FDA, Hospital, Nursing, Magic, Terminology, Industry, OTCQB, Forward-looking statement, Practitioner, Consumer electronics, Medicine, Risk management

SCOTTSDALE, Ariz, Sept. 8, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is excited to announce that the Company is exhibiting its flagship product, the WellnessPro Plus, at the world renowned PAINWeek national conference event (www.painweek.org) this week from September 6 thru September 9 at the Cosmopolitan Hotel in the heart of the Las Vegas strip.

Key Points: 
  • PAINWeek 2021 was the largest pain conference in the United States, drawing over 1,500 attendees in the pain management field.
  • Interested attendees are invited to visit the Electromedical booth and try the WellnessPro Plus firsthand to experience the magic of drug-free pain relief.
  • "PAINWeek offers us the perfect venue to demonstrate the power and efficacy of our core technology," remarked Matthew Wolfson, Founder and CEO of Electromedical.
  • PAINWeek has been a leading resource for frontline practitioners treating acute and chronic pain for over 15 years.

Electromedical Technologies Announces Significant Debt Reduction through Restructuring and Conversion into Restricted Common Shares of the Company

Retrieved on: 
Wednesday, July 20, 2022
Goal, OTC Markets Group, Trust, CEO, Forward-looking statement, Research, Private Securities Litigation Reform Act, Retirement, Pain management, Pain, FDA, Company, Vibration, Terminology, OTC, Security (finance), Bank

Matthew Wolfson, CEO of the Company, commented, "This is a significant event for our Company.

Key Points: 
  • Matthew Wolfson, CEO of the Company, commented, "This is a significant event for our Company.
  • With the newly issued restricted shares, the former debt holder is now a long-term partner with the Company.
  • We thank this investor for their faith and trust in this management team and in our Company.
  • Developing and manufacturing bioelectronics products since 2004, Electromedical Technologies grew over time into a serious competitor in the electrotherapy market.

Electromedical Technologies Adds Former Aerospace CEO and Current Management Expert Lee Benson to Board of Directors

Retrieved on: 
Tuesday, June 14, 2022
Pain, Goal, Execute, OTCQB, GE, Company, Board of directors, Research, Forward-looking statement, CEO, Retirement, University, ETW, FDA, Growth, Private Securities Litigation Reform Act, Russian Venture Company, Bell, Board, Culture, Benson, Textron Aviation, Defence Bioengineering and Electromedical Laboratory, Loss, Terminology, Management, Risk management, Hawker, Textron

Lee can help us reach higher levels of growth, culture and execution."

Key Points: 
  • Lee can help us reach higher levels of growth, culture and execution."
  • Lee Benson started his career as the first employee in a small company providing specialty electroplating services to repair aircraft components.
  • Benson sold Able Aerospace to global powerhouse Textron Aviation in a Nine-figure deal.
  • After he secured the deal, Lee founded ETW to help other businesses achieve maximum success and profit from his experience and expertise.

Electromedical Technologies Announces Financial and Operational Highlights for the Three Months Ended March 31, 2022

Retrieved on: 
Tuesday, May 24, 2022
Pain, Company, Loss, Private Securities Litigation Reform Act, Wellness, Investment, Goal, Three Months Gone, Research, FDA, Industry, Retirement, Defence Bioengineering and Electromedical Laboratory, Forward-looking statement, Wolfson, University, Terminology, Growth, OTCQB, Business, CEO, Fast food, Management, Pharmaceutical industry, Risk management, Marketing

SCOTTSDALE, Ariz., May 24, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three months ended March 31, 2022.

Key Points: 
  • SCOTTSDALE, Ariz., May 24, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three months ended March 31, 2022.
  • Financial Performance Highlights for the Three Months Ended Mar 31, 2022
    Operational Highlights for the Three Months Ended Mar 31, 2022
    Continued investments in Marketing and Sales initiatives.
  • Made strong R&D gains in development of new product line targeting October 2022 full commercial launch.
  • The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.